Clovis Oncology Gross Profit

The latest gross profit for CLVS is $100M as of September 2022. That compares with $120M in the prior-year period — down 16.6% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Clovis Oncology's historical trend and sector peers before judging valuation or financial health.

Over the past year, CLVS's gross profit moved from $120M to $100M — a 16.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Clovis Oncology's operating scale or balance-sheet position.

Against Healthcare companies, CLVS currently prints $100M for gross profit, while the sector average sits near $67B. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at Clovis Oncology's growth, margins, and balance sheet.

A gross profit figure of $100M for CLVS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting CLVS's gross profit ($100M), review year-over-year change from $120M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.